E-LIB Suche - Ergebnisse für: Maes, Bart

1

WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFEC..:

Barratt, Jonathan ; Maes, Bart ; Israni, Rubeen...
Kidney International Reports. 9 (2024) 4 - p. S164 , 2024

Link: https://doi.org/10.1016/..

2

Mechanisms of Political Responsiveness: The Information Sou..:

Willems, Evelien ; Maes, Bart ; Walgrave, Stefaan
Political Research Quarterly. , 2024

Link: https://doi.org/10.1177/..

3

#123 Impact of atacicept on hematuria in IGA nephropathy: p..:

Floege, Jürgen ; Barratt, Jonathan ; Maes, Bart...
Nephrology Dialysis Transplantation. 39 (2024) Supplement_1 - p. , 2024

Link: https://doi.org/10.1093/..

4

WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, B..:

Barratt, Jonathan ; Maes, Bart ; Lin, Celia...
Kidney International Reports. 9 (2024) 4 - p. S158 , 2024

Link: https://doi.org/10.1016/..

5

A phase 2b, randomized, double-blind, placebo-controlled, c..:

Lafayette, Richard ; Barbour, Sean ; Israni, Rubeen...
Kidney International. 105 (2024) 6 - p. 1306-1315 , 2024

Link: https://doi.org/10.1016/..

6

WCN24-342 ATACICEPT IN IGA NEPHROPATHY: CONTINUED PROTECTIV..:

Barratt, Jonathan ; Maes, Bart ; Israni, Rubeen...
Kidney International Reports. 9 (2024) 4 - p. S134 , 2024

Link: https://doi.org/10.1016/..

7

Results of a randomized double-blind placebo-controlled Pha..:

Zhang, Hong ; Rizk, Dana V. ; Perkovic, Vlado...
Kidney International. 105 (2024) 1 - p. 189-199 , 2024

Link: https://doi.org/10.1016/..

8

Hypouricaemia in a patient with hereditary xanthinuria type..:

Maes, Bart ; Dedeurwaerdere, Franceska
The Lancet. 403 (2024) 10435 - p. 1493 , 2024

Link: https://doi.org/10.1016/..

9

#812 Phase 2b ORIGIN study open label extension with atacic..:

Lafayette, Richard ; Maes, Bart ; Israni, Rubeen...
Nephrology Dialysis Transplantation. 39 (2024) Supplement_1 - p. , 2024

Link: https://doi.org/10.1093/..

10

Efficacy and safety of sparsentan versus irbesartan in pati..:

Rovin, Brad H ; Barratt, Jonathan ; Heerspink, Hiddo J L...
The Lancet. 402 (2023) 10417 - p. 2077-2090 , 2023

Link: https://doi.org/10.1016/..

11

Targeting the Alternative Complement Pathway With Iptacopan..:

Rizk, Dana V. ; Rovin, Brad H. ; Zhang, Hong...
Kidney International Reports. 8 (2023) 5 - p. 968-979 , 2023

Link: https://doi.org/10.1016/..

12

#3704 EU REGION-SPECIFIC CARDIOVASCULAR EVENT DATA FOR DAPR..:

Wheeler, David C ; Amenos, Aleix Cases ; Combe, Christian...
Nephrology Dialysis Transplantation. 38 (2023) Supplement_1 - p. , 2023

Link: https://doi.org/10.1093/..

13

#3848 ORIGIN TRIAL: 24-WK PRIMARY ANALYSIS OF A RANDOMIZED,..:

Lafayette, Richard ; Maes, Bart ; Lin, Celia...
Nephrology Dialysis Transplantation. 38 (2023) Supplement_1 - p. , 2023

Link: https://doi.org/10.1093/..

14

A meta-analysis of GFR slope as a surrogate endpoint for ki..:

Inker, Lesley A. ; Collier, Willem ; Greene, Tom...
Nature Medicine. 29 (2023) 7 - p. 1867-1876 , 2023

Link: https://doi.org/10.1038/..

15

Sparsentan in patients with IgA nephropathy: a prespecified..:

Heerspink, Hiddo J L ; Radhakrishnan, Jai ; Alpers, Charles E...
The Lancet. 401 (2023) 10388 - p. 1584-1594 , 2023

Link: https://doi.org/10.1016/..